SLC27A2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4355848	1.00	1/20
SCHEMBL29519105	1.00	1/20
SCHEMBL14823262	0.76	1/20
SCHEMBL12315873	0.76	1/20
SCHEMBL4201238	0.74	1/20
SCHEMBL4354096	0.73	1/20
SCHEMBL24571119	0.73	1/20
SCHEMBL24571274	0.73	1/20
SCHEMBL4983286	0.73	1/20
SCHEMBL12315860	0.72	1/20
SCHEMBL22571267	0.70	1/20
SCHEMBL22571281	0.70	1/20
SCHEMBL4982831	0.70	1/20
SCHEMBL4356626	0.69	1/20
SCHEMBL4985793	0.69	1/20
SCHEMBL22571289	0.69	1/20
SCHEMBL6274028	0.67	1/20
SCHEMBL24571271	0.66	1/20
SCHEMBL4354282	0.65	1/20
SCHEMBL22571262	0.65	1/20

Clinical trials — most relevant to SLC27A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Bezafibrate Trial in CPT2 Deficiency	PHASE3	UNKNOWN
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC	PHASE1/PHASE2	UNKNOWN
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	PHASE2	COMPLETED
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension	PHASE1	COMPLETED
Bioavailability of Paracetamol, Amoxicillin and Talinolol Before, Immediately and One Year After Gastric Bypass Operation	PHASE1	COMPLETED
Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy	EARLY_PHASE1	COMPLETED
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise	nan	COMPLETED
Potential Association of a Common L-FABP Polymorphism With Lipid-induced Hepatic Insulin Resistance	nan	COMPLETED
Tissue Lipids and Insulin Resistance	nan	WITHDRAWN
MARS: Magnetic Resonance Study: A Novel Assessment of Placental Function	nan	COMPLETED
Effect of a PPAR-Alpha Agonist on the Age Related Changes in Myocardial Metabolism and Mechanical Function	nan	UNKNOWN
for Adipose Tissue DIabetes VAriants (fATDIVA)	nan	COMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Intraumbilical Amino Acids and Glucose Supplementation Via Port by Severe IUGR in Human Fetuses	nan	COMPLETED
Systemic Biomarkers of Brain Injury From Hyperammonemia	nan	RECRUITING
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
High Fat Diet for Cardiac Metabolic Reprogramming	nan	RECRUITING
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
Lifestyle Intervention in Preparation for Pregnancy (LIPP)	nan	COMPLETED
Effects of Parenteral L-carnitine Supplementation in Premature Neonates	nan	COMPLETED
The RolE oF Androgen Excess in MUscle Energy MetaboLism in Women With PolyCystic Ovary Syndrome (REFUEL PCOS) Study 2	nan	UNKNOWN
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
Lactate Profile and Fat Oxidation During Exercise	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC27A2 binder may also engage these)

Protein	Name	Similarity
P97524	—	1.000	P97524 →
O35488	—	0.999	O35488 →
E9Q9W4	—	0.999	E9Q9W4 →
Q9Y2P4	—	0.995	Q9Y2P4 →
P38225	—	0.991	P38225 →
O22898	—	0.991	O22898 →
Q8J0E9	—	0.990	Q8J0E9 →
Q9ES38	—	0.989	Q9ES38 →
M4ISH1	—	0.988	M4ISH1 →
Q55DR6	—	0.987	Q55DR6 →
Q9T0A0	—	0.987	Q9T0A0 →
O42633	—	0.986	O42633 →
P30624	—	0.985	P30624 →
Q6BQF2	—	0.985	Q6BQF2 →
Q4LDG0	—	0.984	Q4LDG0 →
Q9NUB1	—	0.984	Q9NUB1 →
Q9C7W4	—	0.984	Q9C7W4 →
Q9T009	—	0.984	Q9T009 →
Q99NB1	—	0.984	Q99NB1 →
D7PHZ3	—	0.983	D7PHZ3 →
Q9P7D7	—	0.983	Q9P7D7 →
P9WEY3	—	0.983	P9WEY3 →
Q8K009	—	0.983	Q8K009 →
Q21166	—	0.982	Q21166 →
O60011	—	0.982	O60011 →
Q9XIA9	—	0.981	Q9XIA9 →
Q6FLU2	—	0.981	Q6FLU2 →
Q01574	—	0.981	Q01574 →
Q8NJN3	—	0.980	Q8NJN3 →
A6UED8	—	0.980	A6UED8 →